Menu

CDC Director Takes a $165,300 Pay Cut

Robert Redfield’s record-setting salary was nearly double that of his predecessors.

May 9, 2018
Diana Kwon

WIKIMEDIA, JAVERT2113

Robert Redfield, the new director for the Centers for Disease Control and Prevention (CDC), has agreed to have his controversial $375,000 salary reduced to $209,700, Caitlin B. Oakley, a spokesperson for the Department of Health and Human Services (HHS), told reporters yesterday (May 8).

“Dr. Redfield did not want his compensation to become a distraction from the important work of the C.D.C. and asked that his salary be reduced,” Oakley said, according to The New York Times. “Dr. Redfield is being paid in accordance with the formula used to pay the prior three C.D.C. directors.”

According to the Times, Redfield’s initial pay was granted through Title 42, a provision that allows HHS to offer salaries higher than the approved government rates to scientists who possess exceptional qualities.

After being assigned the role of director in March, Redfield was granted a salary that was almost double that of his predecessors. According to The Washington Post, the last two directors, Brenda Fitzgerald and Thomas Frieden, received $193,700 and $219,700, respectively.

Redfield’s initial salary “is an exceptional amount of money for what we’ve seen in the past for (CDC) directors,” Angela Beck, a University of Michigan researcher who studies public health workforce issues, told the Associated Press in April.

On April 26, shortly after news reports revealed Redfield’s salary, Senator Patty Murray (D-Wash) penned a letter to HHS Secretary Alex Azar inquiring why Redfield was receiving significantly higher pay than his predecessors, other public health officials, and his boss. “It is difficult to understand why someone with limited public health experience, particularly in a leadership role, is being disproportionately compensated for his work as compared to other accomplished scientists and public health leaders in comparable roles within the federal government,” she wrote.

A few days later, HHS stated that Redfield was pushing to have his salary reduced.

See “AIDS Researcher Emerges as Top Candidate to Head CDC

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.